Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season.
Over the next few years, immuno-oncology companies, which harness the immune system to fight illnesses such as cancer, faces strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.
The 4 immuno-oncology stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 3.9%.
In light of this news, share prices of the companies have held steady as they are up 3.8% on average since the latest earnings results.
Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ:NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology.
Natera reported revenues of $501.8 million, up 36.5% year on year. This print exceeded analysts’ expectations by 12.5%. Overall, it was an exceptional quarter for the company with full-year revenue guidance exceeding analysts’ expectations and a solid beat of analysts’ EPS estimates.
“We delivered another strong quarter, with volume growth across the business, including a record growth quarter for Signatera,” said Steve Chapman, chief executive officer of Natera.
Natera pulled off the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise of the whole group. Unsurprisingly, the stock is up 2.5% since reporting and currently trades at $166.95.
We think Natera is a good business, but is it a buy today? Read our full report here, it’s free.
Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for cancer and inflammatory diseases.
Incyte reported revenues of $1.05 billion, up 19.5% year on year, outperforming analysts’ expectations by 6.4%. The business had an exceptional quarter with a solid beat of analysts’ EPS estimates.
The market seems happy with the results as the stock is up 13.3% since reporting. It currently trades at $67.42.
Is now the time to buy Incyte? Access our full analysis of the earnings results here, it’s free.
